Compare SCLX & CNVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCLX | CNVS |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | United States | United States |
| Employees | 34 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Consumer Electronics/Video Chains |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.5M | 54.7M |
| IPO Year | N/A | 2016 |
| Metric | SCLX | CNVS |
|---|---|---|
| Price | $6.30 | $2.48 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 97.8K | ★ 137.7K |
| Earning Date | 04-10-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 108.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $78,181,000.00 |
| Revenue This Year | $122.52 | N/A |
| Revenue Next Year | $186.30 | $84.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 59.13 |
| 52 Week Low | $4.20 | $1.77 |
| 52 Week High | $34.27 | $7.39 |
| Indicator | SCLX | CNVS |
|---|---|---|
| Relative Strength Index (RSI) | 41.26 | 47.64 |
| Support Level | $6.20 | $2.31 |
| Resistance Level | $7.77 | $2.56 |
| Average True Range (ATR) | 0.77 | 0.12 |
| MACD | -0.20 | -0.01 |
| Stochastic Oscillator | 12.64 | 24.24 |
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Cineverse Corp is a main streaming technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, Podcast and other, and Other non-recurring.